×
About 47,144 results

ALLMedicine™ Colon Cancer Center

Research & Reviews  22,275 results

Factors associated with colon cancer early, intermediate and late recurrence after surg...
https://doi.org/10.1111/ecc.13317
European Journal of Cancer Care REFERENCES; Orive M, Anton A et. al.

Sep 18th, 2020 - To identify factors associated with early, intermediate or late recurrence colon cancer recurrence. A total of 1,732 consecutive patients with colon cancer were recruited and followed for a period of 5 years. Recurrence at 1 year (early), from 1 t...

Ginsenoside Rg3 enhances the anticancer effect of 5‑FU in colon cancer cells via the PI...
https://doi.org/10.3892/or.2020.7728
Oncology Reports; Hong S, Cai W et. al.

Sep 18th, 2020 - Chemotherapy is one of the most commonly used treatments for patients with advanced colon cancer, yet the toxicity of chemotherapy agents, such as 5‑fluorouracil (5‑FU), limits the effectiveness of chemotherapy. Ginsenoside Rg3 (Rg3) is an active ...

Can Oral Tolerance Explain the Inconsistencies Associated with Total Dietary Diversity ...
https://doi.org/10.1080/01635581.2020.1819349
Nutrition and Cancer; Jabbari M, Barati M et. al.

Sep 17th, 2020 - Among the gastrointestinal tract cancers, the risk of colon cancer is strongly dependent on dietary factors. For the first time in the current review, all the original case-control studies, associated with the correlation between total dietary div...

Two-dimensional (2-D) vs. three-dimensional (3-D) laparoscopic right hemicolectomy with...
https://doi.org/10.1007/s00464-020-07977-8
Surgical Endoscopy; Portale G, Pedon S et. al.

Sep 17th, 2020 - There are few reports comparing safety and efficacy of 2-D and 3-D video technology in laparoscopic right hemicolectomy. The aim of the study was to assess the short-term results of laparoscopic right hemicolectomy (LHR) with intracorporeal anasto...

A prospective, single-arm, multicenter trial of diverting stoma followed by neoadjuvant...
https://doi.org/10.1097/SLA.0000000000004494
Annals of Surgery; Ishibe A, Watanabe J et. al.

Sep 17th, 2020 - Obstructive colorectal cancer is locally advanced colorectal cancer with a poor prognosis. The effect of neoadjuvant chemotherapy for obstructive colon cancer is unclear. We conducted the first prospective clinical trial of neoadjuvant chemotherap...

see more →

Guidelines  77 results

Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and ...
https://doi.org/10.1016/j.annonc.2020.06.022
Annals of Oncology : Official Journal of the European Society for Medical Oncology; Argilés G, Tabernero J et. al.

Jul 23rd, 2020 - Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2020|Argilés G,Tabernero J,Labianca R,Hochhauser D,Salazar R,|

Alberto F. Sobrero, MD, on Colon Cancer: Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy for Stage III Disease
https://ascopost.com/videos/asco20-virtual-scientific-program/alberto-sobrero-on-adjuvant-oxaliplatin-and-fluoropyrimidine-based-therapy-for-stage-iii-colon-cancer/

May 31st, 2020 - Alberto F. Sobrero, MD, of the Ospedale San Martino, discusses final results of the IDEA study, which supported the use of 3 months of adjuvant CAPOX, vs 6 months, for most patients with stage III colon cancer. The shorter treatment duration reduc...

Jeffrey A. Meyerhardt, MD, MPH, on Colon Cancer: Celecoxib and FOLFOX for Stage III Disease
https://ascopost.com/videos/asco20-virtual-scientific-program/jeffrey-meyerhardt-on-celecoxib-and-folfox-for-stage-iii-colon-cancer/

May 29th, 2020 - Jeffrey A. Meyerhardt, MD, MPH, of Dana-Farber Cancer Institute, discusses results from the CALGB/SWOG 80702 trial of celecoxib plus standard adjuvant therapy with fluorouracil, leucovorin, and oxaliplatin (FOLFOX). Adding celecoxib to standard ch...

Final IDEA Collaboration Results Support Just 3 Months of Adjuvant CAPOX for Most Patients With Stage III Colon Cancer
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200177/full/

May 28th, 2020 - Prospective evaluation of nearly 13,000 individuals with stage III colon cancer found minimal difference in 5-year overall survival (OS) with 3 versus 6 months of adjuvant CAPOX or FOLFOX for the majority of patients, according to the final result...

First-Line Win for Anti-PD-1 Drug in Advanced Colon Cancer
https://www.medpagetoday.com/meetingcoverage/asco/86763

May 28th, 2020 - Patients with untreated heavily mutated metastatic colorectal cancer (mCRC) lived twice as long without disease progression when they received an immune checkpoint inhibitor instead of chemotherapy, a randomized trial showed.

see more →

Drugs  127 results see all →

Clinicaltrials.gov  23,561 results

Factors associated with colon cancer early, intermediate and late recurrence after surg...
https://doi.org/10.1111/ecc.13317
European Journal of Cancer Care REFERENCES; Orive M, Anton A et. al.

Sep 18th, 2020 - To identify factors associated with early, intermediate or late recurrence colon cancer recurrence. A total of 1,732 consecutive patients with colon cancer were recruited and followed for a period of 5 years. Recurrence at 1 year (early), from 1 t...

Ginsenoside Rg3 enhances the anticancer effect of 5‑FU in colon cancer cells via the PI...
https://doi.org/10.3892/or.2020.7728
Oncology Reports; Hong S, Cai W et. al.

Sep 18th, 2020 - Chemotherapy is one of the most commonly used treatments for patients with advanced colon cancer, yet the toxicity of chemotherapy agents, such as 5‑fluorouracil (5‑FU), limits the effectiveness of chemotherapy. Ginsenoside Rg3 (Rg3) is an active ...

Can Oral Tolerance Explain the Inconsistencies Associated with Total Dietary Diversity ...
https://doi.org/10.1080/01635581.2020.1819349
Nutrition and Cancer; Jabbari M, Barati M et. al.

Sep 17th, 2020 - Among the gastrointestinal tract cancers, the risk of colon cancer is strongly dependent on dietary factors. For the first time in the current review, all the original case-control studies, associated with the correlation between total dietary div...

Two-dimensional (2-D) vs. three-dimensional (3-D) laparoscopic right hemicolectomy with...
https://doi.org/10.1007/s00464-020-07977-8
Surgical Endoscopy; Portale G, Pedon S et. al.

Sep 17th, 2020 - There are few reports comparing safety and efficacy of 2-D and 3-D video technology in laparoscopic right hemicolectomy. The aim of the study was to assess the short-term results of laparoscopic right hemicolectomy (LHR) with intracorporeal anasto...

A prospective, single-arm, multicenter trial of diverting stoma followed by neoadjuvant...
https://doi.org/10.1097/SLA.0000000000004494
Annals of Surgery; Ishibe A, Watanabe J et. al.

Sep 17th, 2020 - Obstructive colorectal cancer is locally advanced colorectal cancer with a poor prognosis. The effect of neoadjuvant chemotherapy for obstructive colon cancer is unclear. We conducted the first prospective clinical trial of neoadjuvant chemotherap...

see more →

News  1,005 results

Alberto F. Sobrero, MD, on Colon Cancer: Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy for Stage III Disease
https://ascopost.com/videos/asco20-virtual-scientific-program/alberto-sobrero-on-adjuvant-oxaliplatin-and-fluoropyrimidine-based-therapy-for-stage-iii-colon-cancer/

May 31st, 2020 - Alberto F. Sobrero, MD, of the Ospedale San Martino, discusses final results of the IDEA study, which supported the use of 3 months of adjuvant CAPOX, vs 6 months, for most patients with stage III colon cancer. The shorter treatment duration reduc...

Jeffrey A. Meyerhardt, MD, MPH, on Colon Cancer: Celecoxib and FOLFOX for Stage III Disease
https://ascopost.com/videos/asco20-virtual-scientific-program/jeffrey-meyerhardt-on-celecoxib-and-folfox-for-stage-iii-colon-cancer/

May 29th, 2020 - Jeffrey A. Meyerhardt, MD, MPH, of Dana-Farber Cancer Institute, discusses results from the CALGB/SWOG 80702 trial of celecoxib plus standard adjuvant therapy with fluorouracil, leucovorin, and oxaliplatin (FOLFOX). Adding celecoxib to standard ch...

Final IDEA Collaboration Results Support Just 3 Months of Adjuvant CAPOX for Most Patients With Stage III Colon Cancer
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200177/full/

May 28th, 2020 - Prospective evaluation of nearly 13,000 individuals with stage III colon cancer found minimal difference in 5-year overall survival (OS) with 3 versus 6 months of adjuvant CAPOX or FOLFOX for the majority of patients, according to the final result...

First-Line Win for Anti-PD-1 Drug in Advanced Colon Cancer
https://www.medpagetoday.com/meetingcoverage/asco/86763

May 28th, 2020 - Patients with untreated heavily mutated metastatic colorectal cancer (mCRC) lived twice as long without disease progression when they received an immune checkpoint inhibitor instead of chemotherapy, a randomized trial showed.

Guidelines on delaying cancer surgery during COVID-19
https://www.mdedge.com/surgery/article/219649/coronavirus-updates/guidelines-delaying-cancer-surgery-during-covid-19/page/0/1?channel=263

Mar 26th, 2020 - Colorectal Cancer Surgery Guidance for colorectal cancer surgery is also split into the three phases of the pandemic. Phase I would include cases needing surgical intervention as soon as feasible, while recognizing that the status of each hospital.

see more →

Patient Education  99 results see all →